Detalhe da pesquisa
1.
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med
; 387(24): 2220-2231, 2022 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36507690
2.
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.
Blood
; 138(10): 836-846, 2021 09 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34115103
3.
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
Blood
; 137(5): 600-609, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33538797
4.
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
N Engl J Med
; 380(23): 2225-2236, 2019 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31166681
5.
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.
Blood
; 136(23): 2628-2637, 2020 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32785666
6.
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Blood
; 135(26): 2402-2412, 2020 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32206772
7.
The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study.
Haematologica
; 107(1): 134-142, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33327712
8.
Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients.
Haematologica
; 107(3): 615-624, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730841
9.
Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma.
BMC Cancer
; 22(1): 231, 2022 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35236331
10.
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med
; 378(12): 1107-1120, 2018 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29562156
11.
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.
Blood
; 134(2): 111-122, 2019 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31023700
12.
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
Blood
; 133(26): 2765-2775, 2019 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30862645
13.
Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440).
Haematologica
; 106(11): 2834-2844, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33121235
14.
Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma.
Haematologica
; 109(4): 1269-1273, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37855035
15.
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL).
Am J Hematol
; 94(9): 1002-1006, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31222797
16.
Utility of Breast MRI for Further Evaluation of Equivocal Findings on Digital Breast Tomosynthesis.
AJR Am J Roentgenol
; 211(5): 1171-1178, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30207789
17.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
N Engl J Med
; 370(12): 1101-10, 2014 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24401022
18.
Pulmonary Artery Pseudoaneurysms: Clinical Features and CT Findings.
AJR Am J Roentgenol
; 208(1): 84-91, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27656954
19.
Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.
Blood
; 133(5): 494-497, 2019 01 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-30455380
20.
Addition of tomosynthesis to conventional digital mammography: effect on image interpretation time of screening examinations.
Radiology
; 270(1): 49-56, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24354377